Acute myeloid leukemia (AML) with mast cell (MC) differentiation was recently described as an aggressive subgroup of AML cases. The objectives of this study were to assess the flow cytometric immunophenotypic features of AML-MC...
Read MoreAcute myeloid leukemia (AML) is a type of blood cancer with diverse genetic variations and DNA methylation alterations. By studying the interaction of gene mutations, expression, and DNA methylation, we aimed to gain valuable...
Read More
THURSDAY, May 16, 2024 (HealthDay News) — For older adults with acute myeloid leukemia...
Read MoreThe prognosis of elderly AML patients had not even been improved by using hypomethylating agents; however, synergistic effect of combining azacitidin with venetoclax had resulted in a remarkable therapeutic advance. Our goal was...
Read MoreIn addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT ) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of...
Read MoreStudies have associated the development of pulmonary leukemia with the activation of the complement system. However, the roles and mechanisms of complement system-related genes (CSRGs) in acute myeloid leukemia (AML) have not...
Read MoreAntifungal prophylaxis with a mold-effective agent has led to a substantial decrease in invasive infections caused by Aspergillus spp. in the management of patients with acute myeloid leukemia undergoing induction chemotherapy....
Read More
Research from ASH 2023 showed standard treatment options lack efficacy for patients who are positive for the TP53 mutation with AML.
Read MorePalliative care is integral to symptom management, and we examined its relationship with income, education, and Medicaid expansion in AML. This was a retrospective cross-sectional study using the National Cancer Database...
Read More
Study identifies 85 genes linked to Acute Myeloid Leukemia prognosis, leading to a five-gene risk...
Read MoreVenetoclax + hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective in the current retrospective study of 301...
Read MoreTo investigate the safety and the short-term efficacy of venetoclax combined with azacitidine followed by cladribine (VAC regimen) in children with refractory/ relapsed acute myeloid leukemia (AML).The clinical data, treatment...
Read More
The Interferon-induced protein with tetratricopeptide repeat (IFIT) family, IFIT1/2/3/5, play an...
Read More![[How did the survival of acute myeloid leukemia change over the last ten years in our unit?].](https://cdn.physiciansweekly.com/wp-content/uploads/2022/12/bresat-cancer-cell-tumor.jpg)
Acute myeloid leukemia (AML) is a hematological malignancy with high mortality rate. The treatment...
Read MorePatients with relapsed or refractory acute myeloid leukemia (R/R AML) and FLT3-internal tandem duplication (FLT3-ITD) respond infrequently to salvage chemotherapy.To investigate the efficacy of sorafenib plus triplet therapy...
Read More
Acute myeloid leukemia (AML) is a deadly hematological malignancy characterized by oncogenic...
Read More
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy with poor prognosis and...
Read More
BCL6 is a transcriptional repressor that regulates multiple genes involved in immune cell...
Read More
CPX-351 demonstrated improved overall survival (OS) versus conventional 3 + 7...
Read More
Acute myeloid leukemia (AML) is a highly heterogeneous subtype of hematological malignancies with...
Read More
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
